EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy

Xinran Wang, Lu Lu, Xiaochuan Hong, Lingling Wu, Chao Yang, You Wang, Wenwen Li, Yuanqin Yang, Dongqing Cao, Wen Di, Liufu Deng

Cell Reports · 2024-02 · 43 (2) · 113712

DOI: 10.1016/j.celrep.2024.113712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024-02. Verfasst von Xinran Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shanghai Key Laboratory of Gynecologic Oncology, State Key Laboratory of Oncogenes and Related Genes, Renji …. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China Stem Cell and Translational Research, Thousand Young Talents Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesNeoplasmsHumansB7-H1 AntigenImmunotherapyCell- and Tissue-Based TherapyMembrane Proteins

Stichwörter der Autor:innen

CD8(+) T cell differentiationCP: CancerCP: ImmunologyPD-L1/PD-1adoptive T cell therapytumor immunity

Substanzen

B7-H1 AntigenMembrane Proteins

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shanghai Key Laboratory of Gynecologic Oncology, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai…
  • Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai 200240, China;…
  • Shanghai Institute of Immunology, Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shang…
  • Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai 200240, China.…

Förderung

  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Thousand Young Talents Program of China
  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • National Key Research and Development Program of China
  • Shanghai Jiao Tong University

Zitieren

APA

Wang, X., Lu, L., Hong, X., Wu, L., Yang, C., Wang, Y., Li, W., Yang, Y., Cao, D., Di, W., & Deng, L. (2024). Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell Reports, 43(2), 113712. https://doi.org/10.1016/j.celrep.2024.113712

Vancouver

Wang X, Lu L, Hong X, Wu L, Yang C, Wang Y, et al. Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell Reports. 2024;43(2):113712. doi:10.1016/j.celrep.2024.113712

BibTeX
@article{Wang2024,
  author = {Wang, Xinran and Lu, Lu and Hong, Xiaochuan and Wu, Lingling and Yang, Chao and Wang, You and Li, Wenwen and Yang, Yuanqin and Cao, Dongqing and Di, Wen and Deng, Liufu},
  title = {Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy},
  journal = {Cell Reports},
  year = {2024},
  volume = {43},
  number = {2},
  pages = {113712},
  doi = {10.1016/j.celrep.2024.113712}
}
Kostenlos starten →